Interleukin-22 Is Frequently Expressed in Small- and Large-Cell Lung Cancer and Promotes Growth in Chemotherapy-Resistant Cancer Cells

• DOI: 10.1097/jto.0b013e31829923c8
• Publication Date: 2013-06-15T07:06:14Z
• Authors: Sebastian Kobold; Stefanie Völk; Till Clauditz; Natascha Jennifer...; Sarah Minner; Amanda Tufman; Peter Düwell; Michael Lindner; Ina Koch; Simon Heidegger; Simon Rothenfußer; Max Schnurr; Rudolf Maria Huber; Waldemar Wilczak; Stefan Endres
• Keywords: Carboplatin

In lung cancer, interleukin-22 (IL-22) expression within primary tissue has been demonstrated, but the frequency and functional consequence of IL-22 signaling have not addressed. This study aims at analyzing cellular effects on carcinoma cell lines prognostic impact in cancer patients.Biological were investigated seven by Western blot, flow cytometry, real-time polymerase chain reaction, proliferation assays. Tumor specimens two cohorts with a total 2300 patients tested for immunohistochemistry. serum concentrations analyzed 103 additional enzyme-linked immunosorbent assay.We found receptor 1 (IL-22-R1) to be expressed six lines. However was only four lines, where induced signal transducer activator transcription 3 phosphorylation increased proliferation. Furthermore, antiapoptotic B-cell lymphoma 2, did rescue tumor cells from carboplatin-induced apoptosis. Cisplatin-resistant showed significant up-regulation IL-22-R1 along stronger proliferative response stimulation. preferentially small- large-cell (58% 46% cases, respectively). However, no correlation between immunohistochemistry prognosis observed.IL-22 is frequently tissue. Enhanced chemotherapy-refractory are indicative protumorigenic function may contribute more aggressive phenotype.